We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Clinical Data Acquires Epidauros Biotechnologie Enhancing Genetic Biomarker Portfolio
News

Clinical Data Acquires Epidauros Biotechnologie Enhancing Genetic Biomarker Portfolio

Clinical Data Acquires Epidauros Biotechnologie Enhancing Genetic Biomarker Portfolio
News

Clinical Data Acquires Epidauros Biotechnologie Enhancing Genetic Biomarker Portfolio

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Clinical Data Acquires Epidauros Biotechnologie Enhancing Genetic Biomarker Portfolio"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Clinical Data, Inc. has announced that it has acquired privately held Epidauros Biotechnologie AG of Bernried, Germany, in a cash transaction valued at 8.75 million euros (or approximately $11.84 million).

Epidauros brings to Clinical Data an established portfolio of genetic biomarkers, expertise in genetic biomarker discovery, relationships with diagnostic companies, and a fast-growing pharmacogenomics services business.

Among the strategic assets acquired by Clinical Data in the transaction is a significant intellectual property portfolio that includes biomarkers in genes relating to prominent drug transporters such as MDR1, OCT1, MRP1, and important cytochrome P450 drug metabolizing genes, such as CYP2B6 and CYP2D6.

MDR1 encodes P-glycoprotein, a key protein involved in drug transport that is known to modulate drug disposition. In addition, the genes CYP2B6, OCT1, and MRP1 are implicated in the absorption, distribution, and metabolism of many drugs that span a variety of therapeutic classes and indications, and are likely to be important in both response and safety profiles for these drugs.

Clinical Data's President and CEO, Drew Fromkin, said, "We are pleased to have completed this highly strategic transaction, which we believe will enhance Clinical Data's ability to bring valuable, proprietary pharmacogenetic tests to market. Epidauros' intellectual property portfolio holds great promise in critical areas related to drug transport and distribution. In turn, these genetic markers should play a significant role in better understanding drug response in individuals."

Advertisement